342 related articles for article (PubMed ID: 8558221)
41. Docetaxel vs doxorubicin in metastatic breast cancer resistant to alkylating chemotherapy.
Chan S
Oncology (Williston Park); 1997 Aug; 11(8 Suppl 8):19-24. PubMed ID: 9364537
[TBL] [Abstract][Full Text] [Related]
42. Phase II trial of docetaxel in patients with advanced cutaneous malignant melanoma previously untreated with chemotherapy.
Bedikian AY; Weiss GR; Legha SS; Burris HA; Eckardt JR; Jenkins J; Eton O; Buzaid AC; Smetzer L; Von Hoff DD
J Clin Oncol; 1995 Dec; 13(12):2895-9. PubMed ID: 8523052
[TBL] [Abstract][Full Text] [Related]
43. Phase I-II studies of docetaxel as a single agent in the treatment of metastatic breast cancer.
Trudeau ME
Semin Oncol; 1999 Jun; 26(3 Suppl 8):21-6. PubMed ID: 10403470
[TBL] [Abstract][Full Text] [Related]
44. Weekly docetaxel in the treatment of elderly patients with advanced breast cancer: a Minnie Pearl Cancer Research Network phase II trial.
Hainsworth JD; Burris HA; Yardley DA; Bradof JE; Grimaldi M; Kalman LA; Sullivan T; Baker M; Erland JB; Greco FA
J Clin Oncol; 2001 Aug; 19(15):3500-5. PubMed ID: 11481356
[TBL] [Abstract][Full Text] [Related]
45. Docetaxel versus doxorubicin in patients with metastatic breast cancer who have failed alkylating chemotherapy: a preliminary report of the randomized phase III trial. 303 Study Group.
Aapro M
Semin Oncol; 1998 Oct; 25(5 Suppl 12):7-11. PubMed ID: 9865705
[TBL] [Abstract][Full Text] [Related]
46. Prospective randomized trial of docetaxel versus doxorubicin in patients with metastatic breast cancer.
Chan S; Friedrichs K; Noel D; Pintér T; Van Belle S; Vorobiof D; Duarte R; Gil Gil M; Bodrogi I; Murray E; Yelle L; von Minckwitz G; Korec S; Simmonds P; Buzzi F; González Mancha R; Richardson G; Walpole E; Ronzoni M; Murawsky M; Alakl M; Riva A; Crown J;
J Clin Oncol; 1999 Aug; 17(8):2341-54. PubMed ID: 10561296
[TBL] [Abstract][Full Text] [Related]
47. Phase I study of docetaxel administered by bi-weekly infusion to patients with metastatic breast cancer.
Shin E; Ishitobi M; Hiraoia M; Kazumasa F; Hideyuki M; Nishisho I; Toshiro S; Yasunori H; Tosimasa T
Anticancer Res; 2000; 20(6C):4721-6. PubMed ID: 11205207
[TBL] [Abstract][Full Text] [Related]
48. Use of docetaxel (Taxotere) in patients with paclitaxel (Taxol) hypersensitivity.
Moon C; Verschraegen CF; Bevers M; Freedman R; Kudelka AP; Kavanagh JJ
Anticancer Drugs; 2000 Aug; 11(7):565-8. PubMed ID: 11036959
[TBL] [Abstract][Full Text] [Related]
49. Taxoids in combination with epirubicin: the search for improved outcomes in breast cancer.
Pagani O
Semin Oncol; 1998 Oct; 25(5 Suppl 12):23-6. PubMed ID: 9865708
[TBL] [Abstract][Full Text] [Related]
50. Preliminary results of multicenter phase II trial of docetaxel (Taxotere) in combination with doxorubicin as first line chemotherapy in Indonesian patients with advanced or metastatic breast cancer.
Muthalib A; Darwis I; Prayogo N; Sutjipto
Gan To Kagaku Ryoho; 2000 May; 27 Suppl 2():498-504. PubMed ID: 10895201
[TBL] [Abstract][Full Text] [Related]
51. Single premedication dose of dexamethasone 20 mg IV before docetaxel administration.
Chouhan JD; Herrington JD
J Oncol Pharm Pract; 2011 Sep; 17(3):155-9. PubMed ID: 20447949
[TBL] [Abstract][Full Text] [Related]
52. Dose-dense therapy with weekly 1-hour paclitaxel infusions in the treatment of metastatic breast cancer.
Seidman AD; Hudis CA; Albanell J; Tong W; Tepler I; Currie V; Moynahan ME; Theodoulou M; Gollub M; Baselga J; Norton L
J Clin Oncol; 1998 Oct; 16(10):3353-61. PubMed ID: 9779712
[TBL] [Abstract][Full Text] [Related]
53. Phase II trial of docetaxel in patients with platinum-refractory advanced ovarian cancer.
Francis P; Schneider J; Hann L; Balmaceda C; Barakat R; Phillips M; Hakes T
J Clin Oncol; 1994 Nov; 12(11):2301-8. PubMed ID: 7964944
[TBL] [Abstract][Full Text] [Related]
54. Phase II trial of docetaxel in patients with stage III and IV non-small-cell lung cancer.
Francis PA; Rigas JR; Kris MG; Pisters KM; Orazem JP; Woolley KJ; Heelan RT
J Clin Oncol; 1994 Jun; 12(6):1232-7. PubMed ID: 7911159
[TBL] [Abstract][Full Text] [Related]
55. Phase III studies of single-agent docetaxel in patients with metastatic breast cancer who have progressed despite previous chemotherapy regimens: preliminary results.
Nabholtz JM; Crown J
Semin Oncol; 1998 Dec; 25(6 Suppl 13):4-9. PubMed ID: 9865685
[TBL] [Abstract][Full Text] [Related]
56. Docetaxel (Taxotere) as monotherapy in the treatment of hormone-refractory prostate cancer: preliminary results.
Picus J; Schultz M
Semin Oncol; 1999 Oct; 26(5 Suppl 17):14-8. PubMed ID: 10604263
[TBL] [Abstract][Full Text] [Related]
57. Weekly administration of docetaxel (Taxotere): summary of clinical data.
Hainsworth JD; Burris HA; Greco FA
Semin Oncol; 1999 Jun; 26(3 Suppl 10):19-24. PubMed ID: 10437747
[TBL] [Abstract][Full Text] [Related]
58. Docetaxel: standard recommended dose of 100 mg/m(2) is effective but not feasible for some metastatic breast cancer patients heavily pretreated with chemotherapy-A phase II single-center study.
Salminen E; Bergman M; Huhtala S; Ekholm E
J Clin Oncol; 1999 Apr; 17(4):1127. PubMed ID: 10561170
[TBL] [Abstract][Full Text] [Related]
59. Single-agent docetaxel in metastatic breast cancer patients pre-treated with anthracyclines and paclitaxel: partial cross-resistance between paclitaxel and docetaxel.
Lin YC; Chang HK; Wang CH; Chen JS; Liaw CC
Anticancer Drugs; 2000 Sep; 11(8):617-21. PubMed ID: 11081452
[TBL] [Abstract][Full Text] [Related]
60. Docetaxel in advanced renal carcinoma. A phase II trial of the National Cancer Institute of Canada Clinical Trials Group.
Mertens WC; Eisenhauer EA; Jolivet J; Ernst S; Moore M; Muldal A
Ann Oncol; 1994 Feb; 5(2):185-7. PubMed ID: 7910480
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]